Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer

KRAS and TP53 mutations, which are the most common genetic drivers of tumorigenesis, are still considered undruggable targets. Therefore, we analyzed these genetic aberrations in metastatic non-small cell lung cancer (NSCLC) for the development of potential therapeutics. One hundred eighty-five cons...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Wang, Yudong, Wang, Zhijie, Piha-Paul, Sarina, Janku, Filip, Subbiah, Vivek, Shi, Naiyi, Hess, Kenneth, Broaddus, Russell, Shan, Baoen, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Lu, Charles, Papadimitrakopoulou, Vali, Heymach, John, Meric-Bernstam, Funda, Fu, Siqing
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2018
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6161801/
https://ncbi.nlm.nih.gov/pubmed/30279957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25947
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge